Cargando…

Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum

BACKGROUND: Combination of platinum derivatives with paclitaxel is currently the standard front line regimen for patients with epithelial ovarian carcinoma, and represents also an active regimen in patients with metastatic breast or unknown primary carcinomas. Measurement of intestinal permeability...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melichar, Bohuslav, Hyšpler, Radomír, Dragounová, Emanuela, Dvořák, Josef, Kalábová, Hana, Tichá, Alena
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1973082/ https://www.ncbi.nlm.nih.gov/pubmed/17688683 http://dx.doi.org/10.1186/1471-2407-7-155

Ejemplares similares

Immunotherapy in mucosal melanoma: a case report and review of the literature
por: Studentova, Hana, et al.
Publicado: (2018)

The estimation of post-transplant lymphocele origin using creatine kinase activity
por: Pacovsky, Jaroslav, et al.
Publicado: (2010)

The Evaluation and Quantitation of Dihydrogen Metabolism Using Deuterium Isotope in Rats
por: Hyspler, Radomir, et al.
Publicado: (2015)

Selected Risk Nutritional Factors for Chemotherapy-Induced Polyneuropathy
por: Grim, Jiri, et al.
Publicado: (2017)

Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor
por: ŠTUDENTOVÁ, HANA, et al.
Publicado: (2016)

SLIDE—Novel Approach to Apocrine Sweat Sampling for Lipid Profiling in Healthy Individuals
por: Kvasnička, Aleš, et al.
Publicado: (2021)

Markers of Perioperative Bowel Complications in Colorectal Surgery Patients
por: Hyšpler, Radomír, et al.
Publicado: (2015)

rIFN-γ-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition
por: Melichar, Bohuslav, et al.
Publicado: (2003)

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
por: Sandercock, J, et al.
Publicado: (2002)

Indoxyl Sulfate Elimination in Renal Replacement Therapy: Influence of Citrate- versus Acetate-Buffering Component during Bicarbonate Dialysis
por: Hyšpler, Radomír, et al.
Publicado: (2018)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
por: Zhao, Hong, et al.
Publicado: (2020)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

The changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma
por: Buka, David, et al.
Publicado: (2017)

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
por: Osman, Mohammed A., et al.
Publicado: (2016)

Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
por: Zhao, Hong, et al.
Publicado: (2021)

Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings
por: Tossetta, Giovanni
Publicado: (2022)

Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study
por: Wang, Liangliang, et al.
Publicado: (2023)

Integrated Analysis of Gene Expression Profiles Associated with Response of Platinum/Paclitaxel-Based Treatment in Epithelial Ovarian Cancer
por: Han, Yong, et al.
Publicado: (2012)

Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
por: Lam, Clarissa, et al.
Publicado: (2022)

Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver
por: Igreja Sá, Ivone Cristina, et al.
Publicado: (2020)

Cell-permeable lanthanide–platinum(iv) anti-cancer prodrugs
por: Yao, Kezi, et al.
Publicado: (2021)

Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
por: Groeneweg, Jolijn W., et al.
Publicado: (2014)

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
por: Kavanagh, John J, et al.
Publicado: (2010)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
por: Ricci, Francesca, et al.
Publicado: (2017)

Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
por: Fu, Siqing, et al.
Publicado: (2022)

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
por: Rob, Lukas, et al.
Publicado: (2022)

CHFR and Paclitaxel Sensitivity of Ovarian Cancer
por: Wahner Hendrickson, Andrea E., et al.
Publicado: (2021)

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
por: Sharma, R, et al.
Publicado: (2009)

Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy
por: Smoter, Marta, et al.
Publicado: (2013)

[(18)F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer
por: Sharma, Rohini, et al.
Publicado: (2019)

Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer
por: Noronha, Vanita, et al.
Publicado: (2012)

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
por: Moreno, Victor, et al.
Publicado: (2021)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma
por: Studentova, Hana, et al.
Publicado: (2023)

Neoadjuvant nivolumab and cabozantinib in advanced renal cell carcinoma in a horseshoe kidney – how to achieve a safe and radical resection? a case report and review of the literature
por: Zemankova, Anezka, et al.
Publicado: (2023)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Exosomes as mediators of platinum resistance in ovarian cancer
por: Crow, Jennifer, et al.
Publicado: (2017)

ATR Inhibitors in Platinum-Resistant Ovarian Cancer
por: Li, Siyu, et al.
Publicado: (2022)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
por: Havasi, Andrei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3a8mv16qckkb2eag1vkfpk7d3i